A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT05565391
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elranatamab — DRUG
    BCMA-CD3 bispecific antibody
  • Standard of care — DRUG
    Standard of care

Study Details

This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, we will use data from the phase 2 clinical trial (MagnetisMM-3). We will also use data from two real-world databases, representing the SOC in clinical practice. This study does not seek any participants for enrollment. We will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help us to know how well elranatamab can be used for RRMM treatment.

Key Dates

Start date
Oct 3, 2022
Status verified
Apr 2024
Primary completion
Nov 4, 2022
Completion
Nov 4, 2022

Study Design

Enrollment
508 participants (actual)

Arms

  • Arm: Elranatamab
    Patients treated with elranatamab from the MagnetisMM-3 trial
  • Arm: Standard of care
    Patients treated with standard-of-care therapies from real-world data sources

Primary Outcome Measure

Objective Response Rate (ORR)-Unweighted Analysis [ Time Frame: From index date until first documentation of progression, death, or the start of new anticancer therapy (median follow-up of 10.4 months for study C1071003 cohort A, 8.8 months and 7.7 months for COTA and Flatiron Health cohorts) ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10001-

Find similar trials in New York, NY

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Pfizer· New York, NY

Related Studies